In 2009, total funding for European and U.S. biotechs
dwarfed the dismal levels seen in 2008. The European sector raised $6.3 billion
last year, up 202% from $2.1 billion in 2008, driven by three companies. Qiagen
N.V. (Xetra:QIA; NASDAQ:QGEN) pulled in $640.4 million from a follow-on in
2009, and Elan Corp. plc